Author

Edwin Roger Parra

Observed names: E PARRA, E Parra, E R Parra, E. Parra, E.R. Parra, Edwin Parra, Edwin R Parra, Edwin R. Parra, Edwin R. Parra Cuentas, Edwin R. Parra Cuentas Cuentas, Edwin Roger Parra Cuentas, Edwin Roger Parra Cuentes, Parra, Edwin, Roger Parra, Edwin

Observed institutions: The University of Texas MD Anderson Cancer Center, The University of Texas System, Universidade de São Paulo, Chinese Academy of Medical Sciences & Peking Union Medical College, Instituto Adolfo Lutz, Peking Union Medical College Hospital, Adaptive Biotechnologies (United States), ORCID, Fundação Faculdade de Medicina, Boehringer Ingelheim (United States)

ORCID: 0000-0001-9068-1636

Observed ORCID: 0000-0001-9068-1636

OpenAlex ID: A5043477787

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

2018 · Ferdinandos Skoulidis, Michael E. Goldberg, et al. · Cancer Discovery · 1,635

Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

2015 · Ferdinandos Skoulidis, Lauren A. Byers, et al. · Cancer Discovery · 933

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

2020 · Mariano Provencio, Ernest Nadal, et al. · The Lancet Oncology · 840

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

2018 · Yinghong Wang, Diana H. Wiesnoski, et al. · Nature Medicine · 736

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

2021 · Tina Cascone, William N. William, et al. · Nature Medicine · 610

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

2015 · Milena P. Mak, Pan Tong, et al. · Clinical Cancer Research · 535

Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

2016 · Yanyan Lou, Lixia Diao, et al. · Clinical Cancer Research · 438

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion

2020 · David H. Peng, Bertha Leticia Rodriguez, et al. · Nature Communications · 437

A proteogenomic portrait of lung squamous cell carcinoma

2021 · Shankha Satpathy, Karsten Krug, et al. · Cell · 379

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

2020 · Janis M Taube, Guray Akturk, et al. · Journal for ImmunoTherapy of Cancer · 287

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

2017 · Edwin R. Parra, Naohiro Uraoka, et al. · Scientific Reports · 267

Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma

2015 · Daniela Pankova, Yulong Chen, et al. · Molecular Cancer Research · 232

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence

2017 · Alexandre Reuben, Rachel Gittelman, et al. · Cancer Discovery · 223

Comprehensive T cell repertoire characterization of non-small cell lung cancer

2020 · Alexandre Reuben, Jiexin Zhang, et al. · Nature Communications · 220

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

2023 · Tina Cascone, Cheuk H. Leung, et al. · Nature Medicine · 217

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

2020 · Emily Z. Keung, Melissa Burgess, et al. · Clinical Cancer Research · 214

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

2016 · H Kadara, M Choi, et al. · Annals of Oncology · 200

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma

2023 · Yu Qian, Ana Galan-Cobo, et al. · Cancer Cell · 197

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

2024 · Ferdinandos Skoulidis, Haniel A. Araujo, et al. · Nature · 191

An atlas of epithelial cell states and plasticity in lung adenocarcinoma

2024 · Guangchun Han, Ansam Sinjab, et al. · Nature · 185

Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma

2019 · Xin Hu, Junya Fujimoto, et al. · Nature Communications · 174

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

2018 · Edwin R. Parra, Pamela Villalobos, et al. · Journal for ImmunoTherapy of Cancer · 167

Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients

2016 · Edwin R. Parra, Carmen Behrens, et al. · Clinical Cancer Research · 166

Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis

2023 · Taylor M. Halsey, Anusha S. Thomas, et al. · Science Translational Medicine · 160

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

2022 · Neeta Somaiah, Anthony P Conley, et al. · The Lancet Oncology · 158

Works count: 635

Citation count: 15,680

H-index: 60

I10-index: 135